Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Vorinostat (rINN), also known as suberoylanilide hydroxamic acid (suberoyl+anilide+hydroxamic acid abbreviated as SAHA), is a member of a larger class of compounds that inhibit histone deacetylases (HDAC). Histone deacetylase inhibitors (HDI) have a broad spectrum of epigenetic activities.
Read the full article on WikipediaCutaneous T-cell lymphoma Clinical criteria: Treatment Phase: Initial treatment Patient must have received systemic treatment with chemotherapy, AND Patient must demonstrate relapsed or chemotherapy-refractory disease, AND Patient must be ineligible for stem cell transplant, AND The treatment must be the sole PBS-subsidised therapy for this condition. If the application is submitted through HPOS form upload or mail, it must include: (i) details of the proposed prescription; and (ii) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).
“Vorinostat has been shown to bind to the active site of histone deacetylases and act as a chelator for zinc ions also found in the active site of histone deacetylases. Vorinostat's inhibition of histone deacetylases results in the accumulation of acetylated histones and acetylated proteins, including transcription factors crucial for the expression of genes needed to induce cell differentiation. It acts on class I, II and IV of histone deacetylase. [citation needed]”
“~2 hours (vorinostat and O-glucuronide), 11 hours (4-anilino-4-oxobutanoic acid)”
Working under the parallel aged-care framework? Aged-care equivalent →